Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA
receptor antagonist, to induce rapid (within hours), transient antidepressant effects when …

BACKGROUND: A single subanesthetic (intravenous) IV dose of ketamine might have rapid
but transient antidepressant effects in patients with treatment-resistant depression (TRD) …

Objectives. Research studies have reported impressive antidepressant effects with ketamine
but significant knowledge gaps remain over the best method of administering ketamine, and …

Objective: Ketamine has demonstrated rapid antidepressant effects in patients with
treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this …

Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has
shown rapid antidepressant effects, but small study groups and inadequate control …

Objective: Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has
demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant …

Background Sub-anaesthetic administration of ketamine is an emerging practice in patients
presenting treatment resistant depression (TRD), however several outstanding questions …

Objective: The N-methyl-d-aspartate receptor antagonist ketamine has rapid antidepressant
effects in treatment-resistant major depressive disorder (MDD) and bipolar depression …

Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient
antidepressant effects in patients with treatment-resistant depression, which may be …

Background: The intravenous administration of ketamine, an N-methyl-d-aspartate receptor
antagonist, results in a great improvement of depression symptoms, but it is not clear for how …